C-MET蛋白在甲状腺癌合并颈部淋巴结转移的研究  

Expression of C-MET in thyroid carcinoma with cervical lymph node metastases and its clinical significance

作　　者：郑炳行[1] 师天雄[1] 邓建伟[1] 

机构地区：[1]广东省中山市人民医院普外科,广东中山528403

出　　处：《中国医药科学》2013年第9期26-27,43,共3页China Medicine And Pharmacy

基　　金：广东省中山市人民医院科研课题(200763)

摘　　要：目的探讨C-MET蛋白在甲状腺癌特别是甲状腺乳头状癌中合并有或无颈部淋巴结转移及良性甲状腺组织中的表达及其临床意义。方法回顾性分析我院208例行甲状腺手术患者C-MET蛋白免疫组织化学临床检测资料,设为甲状腺乳头状癌1、甲状腺乳头状癌2、FTC、HTC及非恶性5组,即甲状腺乳头状腺癌有颈部淋巴结转移、甲状腺乳头状腺癌无伴有颈部淋巴结转移、甲状腺滤泡状腺癌、甲状腺髓样癌和非恶性甲状腺组织。结果甲状腺乳头状癌1组的C-MET表达水平明显高于其他4组(P<0.001)。甲状腺乳头状癌2组与FTC组比较,P=0.002;甲状腺乳头状癌2组与良性组比较,差异有统计学意义(P<0.001)。结论 C-MET蛋白表达可作为甲状腺乳头状癌患者合并有淋巴结转移重要预判因素,并与肿瘤的囊外扩展和直接侵犯关系密切。Objective To investigate the expression of C-MET in papillary thyroid carcinoma PTC withcervical lymph node metastases, PTC without cervical lymph node metastases, follicular thyroid carcinoma and benign thyroid disease and the clinical significance. Methods The clinical imunohistochemistry data of 208 patients with thyroid surgery were retrospectively analyzed in our hospital and divided into 5 groups including 70 cases of PTC with cervical lymphnode metastases, 62 cases of PTC without cervical lymph node mestastases,12 cases of follicular thyroid carcinoma, medullary thyroid carcinoma 4 cases of follicular thyroid carcinoma and 60cases of benign thyroid disease. Results The expressed level of C-MET protein of PTC1 group was significantly higher than another group （P 〈 0.001）. The expressed level of C-MET protein of PTC2 group was significantly higher than FTC group （P=0.002）. And the expressed level of C-MET protein of PTC1 group was significantly higher than benign thyroid disease group （P 〈 0.001）. Conclusion The expressed level of C-MET level can be as the significant predicting factor on papillary thyroid carcinoma patients with lymph node metastasis and with close relationship in tumor extracapsular extension and a direct violation.

关 键 词：甲状腺肿瘤 病理学 淋巴转移 C—MET蛋白 

分 类 号：R736.1[医药卫生—肿瘤]